GlassScriptPhysician profile
Bruce I Hindin
NPI 1629071261
$581.20
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $63.75 · 2022: $34.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $177.58 | 2019-2020 | |
| Daiichi Sankyo INC. | $173.12 | 2019 | |
| Horizon Therapeutics Plc | $83.47 | 2019-2020 | |
| Boston Scientific Corporation | $34.49 | 2022 | |
| Arbor Pharmaceuticals, INC. | $32.66 | 2019 | |
| Medtronic USA, INC. | $21.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.93 | 2019 | |
| Biodelivery Sciences International, INC. | $16.41 | 2019 | |
| Kaleo, INC. | $11.73 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Hindin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.